BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Heyman B, Yang Y. Mechanisms of heparanase inhibitors in cancer therapy. Exp Hematol 2016;44:1002-12. [PMID: 27576132 DOI: 10.1016/j.exphem.2016.08.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Ricciuti B, Foglietta J, Chiari R, Sahebkar A, Banach M, Bianconi V, Pirro M. Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications. Med Oncol 2018;35. [DOI: 10.1007/s12032-017-1064-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
2 Chen J, Kawamura T, Sethi MK, Zaia J, Repunte-Canonigo V, Sanna PP. Heparan sulfate: Resilience factor and therapeutic target for cocaine abuse. Sci Rep 2017;7:13931. [PMID: 29066725 DOI: 10.1038/s41598-017-13960-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
3 Fu K, Bai Z, Chen L, Ye W, Wang M, Hu J, Liu C, Zhou W. Antitumor activity and structure-activity relationship of heparanase inhibitors: Recent advances. Eur J Med Chem 2020;193:112221. [PMID: 32222663 DOI: 10.1016/j.ejmech.2020.112221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Pinhal MAS, Melo CM, Nader HB. The Good and Bad Sides of Heparanase-1 and Heparanase-2. Adv Exp Med Biol 2020;1221:821-45. [PMID: 32274740 DOI: 10.1007/978-3-030-34521-1_36] [Reference Citation Analysis]
5 Changyaleket B, Deliu Z, Chignalia AZ, Feinstein DL. Heparanase: Potential roles in multiple sclerosis. J Neuroimmunol 2017;310:72-81. [PMID: 28778449 DOI: 10.1016/j.jneuroim.2017.07.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
6 Mohan CD, Hari S, Preetham HD, Rangappa S, Barash U, Ilan N, Nayak SC, Gupta VK, Basappa, Vlodavsky I, Rangappa KS. Targeting Heparanase in Cancer: Inhibition by Synthetic, Chemically Modified, and Natural Compounds. iScience 2019;15:360-90. [PMID: 31103854 DOI: 10.1016/j.isci.2019.04.034] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
7 Koliesnik IO, Kuipers HF, Medina CO, Zihsler S, Liu D, Van Belleghem JD, Bollyky PL. The Heparan Sulfate Mimetic PG545 Modulates T Cell Responses and Prevents Delayed-Type Hypersensitivity. Front Immunol 2020;11:132. [PMID: 32117279 DOI: 10.3389/fimmu.2020.00132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Yu Y, Williams A, Zhang X, Fu L, Xia K, Xu Y, Zhang F, Liu J, Koffas M, Linhardt RJ. Specificity and action pattern of heparanase Bp, a β-glucuronidase from Burkholderia pseudomallei. Glycobiology 2019;29:572-81. [PMID: 31143933 DOI: 10.1093/glycob/cwz039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
9 Lanzi C, Cassinelli G. Heparan Sulfate Mimetics in Cancer Therapy: The Challenge to Define Structural Determinants and the Relevance of Targets for Optimal Activity. Molecules 2018;23:E2915. [PMID: 30413079 DOI: 10.3390/molecules23112915] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
10 Theodoro TR, Matos LL, Cavalheiro RP, Justo GZ, Nader HB, Pinhal MAS. Crosstalk between tumor cells and lymphocytes modulates heparanase expression. J Transl Med 2019;17:103. [PMID: 30922347 DOI: 10.1186/s12967-019-1853-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
11 Piperigkou Z, Kyriakopoulou K, Koutsakis C, Mastronikolis S, Karamanos NK. Key Matrix Remodeling Enzymes: Functions and Targeting in Cancer. Cancers (Basel) 2021;13:1441. [PMID: 33809973 DOI: 10.3390/cancers13061441] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Kinaneh S, Khamaysi I, Karram T, Hamoud S. Heparanase as a potential player in SARS-CoV-2 infection and induced coagulopathy. Biosci Rep 2021;41:BSR20210290. [PMID: 34132790 DOI: 10.1042/BSR20210290] [Reference Citation Analysis]
13 Tang WQ, Hei Y, Lin J. Heparanase-1 is downregulated in chemoradiotherapy orbital rhabdomyosarcoma and relates with tumor growth as well as angiogenesis. Int J Ophthalmol 2022;15:31-9. [PMID: 35047353 DOI: 10.18240/ijo.2022.01.05] [Reference Citation Analysis]
14 Noda K, Philips BJ, Snyder ME, Phillippi JA, Sullivan M, Stolz DB, Ren X, Luketich JD, Sanchez PG. Heparanase inhibition preserves the endothelial glycocalyx in lung grafts and improves lung preservation and transplant outcomes. Sci Rep 2021;11:12265. [PMID: 34112915 DOI: 10.1038/s41598-021-91777-0] [Reference Citation Analysis]
15 Boittier ED, Gandhi NS, Ferro V, Coombe DR. Cross-Species Analysis of Glycosaminoglycan Binding Proteins Reveals Some Animal Models Are "More Equal" than Others. Molecules 2019;24:E924. [PMID: 30845788 DOI: 10.3390/molecules24050924] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
16 Chandler KB, Costello CE, Rahimi N. Glycosylation in the Tumor Microenvironment: Implications for Tumor Angiogenesis and Metastasis. Cells 2019;8:E544. [PMID: 31195728 DOI: 10.3390/cells8060544] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
17 Masola V, Zaza G, Gambaro G, Franchi M, Onisto M. Role of heparanase in tumor progression: Molecular aspects and therapeutic options. Semin Cancer Biol 2020;62:86-98. [PMID: 31348993 DOI: 10.1016/j.semcancer.2019.07.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
18 Bartolini B, Caravà E, Caon I, Parnigoni A, Moretto P, Passi A, Vigetti D, Viola M, Karousou E. Heparan Sulfate in the Tumor Microenvironment. Adv Exp Med Biol 2020;1245:147-61. [PMID: 32266657 DOI: 10.1007/978-3-030-40146-7_7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
19 Mayfosh AJ, Baschuk N, Hulett MD. Leukocyte Heparanase: A Double-Edged Sword in Tumor Progression. Front Oncol 2019;9:331. [PMID: 31110966 DOI: 10.3389/fonc.2019.00331] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
20 Clayton NS, Wilson AS, Laurent EP, Grose RP, Carter EP. Fibroblast growth factor-mediated crosstalk in cancer etiology and treatment. Dev Dyn 2017;246:493-501. [PMID: 28470714 DOI: 10.1002/dvdy.24514] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
21 Qiu M, Huang S, Luo C, Wu Z, Liang B, Huang H, Ci Z, Zhang D, Han L, Lin J. Pharmacological and clinical application of heparin progress: An essential drug for modern medicine. Biomed Pharmacother 2021;139:111561. [PMID: 33848775 DOI: 10.1016/j.biopha.2021.111561] [Reference Citation Analysis]
22 Parate S, Kumar V, Danishuddin, Hong JC, Lee KW. Computational Investigation Identified Potential Chemical Scaffolds for Heparanase as Anticancer Therapeutics. Int J Mol Sci 2021;22:5311. [PMID: 34156395 DOI: 10.3390/ijms22105311] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
23 Ghiselli G. Heparin Binding Proteins as Therapeutic Target: An Historical Account and Current Trends. Medicines (Basel) 2019;6:E80. [PMID: 31362364 DOI: 10.3390/medicines6030080] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 Ricciuti B, Foglietta J, Bianconi V, Sahebkar A, Pirro M. Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy. Semin Cancer Biol 2019;56:87-99. [PMID: 29128510 DOI: 10.1016/j.semcancer.2017.11.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
25 Wat JM, Audette MC, Kingdom JC. Molecular actions of heparin and their implications in preventing pre-eclampsia. J Thromb Haemost 2018. [PMID: 29877031 DOI: 10.1111/jth.14191] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
26 Cruz LA, Tellman TV, Farach-Carson MC. Flipping the Molecular Switch: Influence of Perlecan and Its Modifiers in the Tumor Microenvironment. Adv Exp Med Biol 2020;1245:133-46. [PMID: 32266656 DOI: 10.1007/978-3-030-40146-7_6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
27 Groult H, Poupard N, Herranz F, Conforto E, Bridiau N, Sannier F, Bordenave S, Piot JM, Ruiz-Cabello J, Fruitier-Arnaudin I, Maugard T. Family of Bioactive Heparin-Coated Iron Oxide Nanoparticles with Positive Contrast in Magnetic Resonance Imaging for Specific Biomedical Applications. Biomacromolecules 2017;18:3156-67. [PMID: 28850787 DOI: 10.1021/acs.biomac.7b00797] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]